Gain From the Weight-Loss Trend With These Stocks

Everyone’s been talking about the drug semaglutide, used to treat Type 2 diabetes. It’s marketed under the brand names Ozempic, Wegovy, and now, Mounjaro. Are any of the drugmakers a buy? Salesforce’s Successful QuarterHP is Having ProblemsMacy’s Misses the Mark  Diabetes Drugs Take OverBiotech FrontrunnersWhy is Pfizer Underperforming?Semaglutide RisksBiotech Stock PicksWhat Higher Yields Mean for Retired ‘Bucket’ Investors Read about topics from this episode.  Salesforce Earnings: Margins Shine As New Signs of Pressure Remove Some LusterHP Earnings: Sales Remain Soft, Although Improvement Is on the Horizon; Shares Fairly ValuedMacy’s Earnings: Lowered Outlook on Waning Spending Overshadows Positives; Shares UndervaluedNovo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look RichObesity Drug Stocks: Time to Buy?  What to watch from Morningstar.Double Trouble: How the Dot-Com and Tech Bubbles CompareWhat to Do as Recession Fears Grip InvestorsJust Where’s the U.S. Economy Headed?Active ETFs Take Off –– 3 Ideas for Investors  Read what our team is writing:Ruth SaldanhaKaren AndersenSusan DziubinskiChristine Benz  Follow us on social media.Ruth Saldanha on Twitter: @karishmaruthFacebook: https://www.facebook.com/MorningstarInc/Twitter: https://twitter.com/MorningstarIncInstagram: https://www.instagram.com/morningstar... LinkedIn: https://www.linkedin.com/company/5161/